INFURO is designed as a monocentric, prospective, randomized, double-blind, cross-over Phase II clinical trial to test the safety and tolerability of furosemide inhalation in patients with dyspnea. Dyspnea is one of the most common symptoms in internal medicine. It has an adverse effect on patients’ quality of life and is also an independent predictor of mortality in patients with cardiovascular and respiratory diseases. However, there is still a lack of safe and effective therapy for causally uncontrollable dyspnoea, particularly in palliative care.
The sponsor of the clinical trial is the University Hospital Hradec Králové, where the study under the leadership of Assoc. MUDr. Vladimír Koblizek, Ph.D. and his colleagues is underway.
The clinical trial was initiated and started in February 2024, currently 17 patients are enrolled out of 102 planned.
CZECRIN Office
Faculty of Medicine, Masaryk University Department of Pharmacology LRI CZECRIN Kamenice 5,625 00 Brno, Česká Republika
Info@czecrin.cz Phone: +420 549 498 165 Phone: +420 725 828 348
